FDA Lifts Clinical Hold on Solid Biosciences Trial for DMD Gene Therapy

The FDA has lifted its clinical hold on Solid Biosciences’ Phase I/II trial for its lead candidate, the Duchenne muscular dystrophy (DMD) gene therapy SGT-001, the company said today.Solid said it has begun activities to resume the clinical trial and plans to reinitiate enrollment “as quickly as possible,” after the FDA acknowledged in a letter that the company answered to its satisfaction all questions related to the clinical hold.“We are pleased to have been able to pro